Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where N. Belluardo is active.

Publication


Featured researches published by N. Belluardo.


Digestive and Liver Disease | 2018

The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

Fabio Salvatore Macaluso; R. Orlando; Walter Fries; Mariangela Scolaro; Antonio Magnano; Dario Pluchino; M. Cappello; Gaetano Cristian Morreale; S. Siringo; Antonino C. Privitera; Concetta Ferracane; N. Belluardo; Nadia Alberghina; M. Ventimiglia; G. Rizzuto; Sara Renna; Mario Cottone; Ambrogio Orlando

BACKGROUND The effectiveness of vedolizumab in real-world practice is under evaluation, while its role in inflammatory bowel disease-associated spondyloarthritis is still unclear. AIMS To report real-world data about the effectiveness of vedolizumab on intestinal and articular symptoms after 10 and 22 weeks of treatment. METHODS Web-based data from the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) were extracted to perform a prospective multicentre observational study. RESULTS 163 patients (84 with Crohns disease and 79 with ulcerative colitis) were included. At week 10, a steroid-free remission was achieved in 71 patients (43.6%), while at week 22 a steroid-free remission was obtained in 40.8% of patients. A response on articular symptoms was reported after 10 weeks of treatment in 17 out of 43 (39.5%) patients with active spondyloarthritis at baseline, and in 10 out of 22 (45.4%) patients at week 22. The only factor associated with articular response was the coexistence of clinical benefit on intestinal symptoms (at week 10: OR 8.471, p = 0.05; at week 22: OR 5.600, p = 0.08). CONCLUSIONS Vedolizumab showed good effectiveness after 10 and 22 weeks of treatment. A subset of patients reported improvement also on articular symptoms, probably as a consequence of the concomitant control of gut inflammation.


Journal of Crohns & Colitis | 2018

A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn’s disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Fabio Salvatore Macaluso; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; Roberto Di Mitri; Filippo Mocciaro; N. Belluardo; G. Scarpulla; Giovanni Magrì; Antonino Trovatello; Antonio Carroccio; Salvatore Genova; Carmelo Bertolami; Roberto Vassallo; Claudio Romano; Michele Citrano; Salvatore Accomando; M. Ventimiglia; Sara Renna; Rosalba Orlando; G. Rizzuto; Serena Porcari; Concetta Ferracane; Mario Cottone; Ambrogio Orlando

Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohns disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. Results A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. Conclusions In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.


Journal of Crohns & Colitis | 2018

P644 Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD)

Fabio Salvatore Macaluso; R. Orlando; Walter Fries; M Scolaro; Antonio Magnano; D Pluchino; M. Cappello; G C Morreale; S. Siringo; A. Privitera; Concetta Ferracane; N. Belluardo; N Alberghina; M. Ventimiglia; G. Rizzuto; Sara Renna; Mario Cottone; Ambrogio Orlando


Journal of Crohns & Colitis | 2018

P577 A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease

Ambrogio Orlando; Fabio Salvatore Macaluso; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; R. Di Mitri; N. Belluardo; G. Scarpulla; G. Magrì; N. Trovatello; Antonio Carroccio; S. Genova; C. Bertolami; R. Vassallo; M. Ventimiglia; Sara Renna; R. Orlando; G. Rizzuto; Mario Cottone


Digestive and Liver Disease Supplements | 2018

Sicilian Network for Inflammatory Bowel Disease (SN-IBD). A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease.

Ambrogio Orlando; Fabio Salvatore Macaluso; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; R. Di Mitri; N. Belluardo; G. Scarpulla; G. Magrì; N. Trovatello; Antonio Carroccio; S. Genova; C. Bertolami; R. Vassallo; M. Ventimiglia; Sara Renna; R. Orlando; G. Rizzuto; Mario Cottone


Digestive and Liver Disease | 2018

OC.02.4 THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD): A COMPARISON OF THE EFFICACY OF CURRENT BIOLOGICS IN CROHN'S DISEASE

Ambrogio Orlando; Fabio Salvatore Macaluso; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; R. Di Mitri; N. Belluardo; G. Scarpulla; G. Magrì; A. Trovatello; Antonio Carroccio; S. Genova; C. Bertolami; R. Vassallo; Claudio Romano; S. Pellegrino; M. Citrano; Salvatore Accomando; M. Ventimiglia; Sara Renna; R. Orlando; G. Rizzuto; Concetta Ferracane; Mario Cottone


Digestive and Liver Disease | 2018

P.02.4 EFFECTIVENESS OF VEDOLIZUMAB ON INTESTINAL AND ARTICULAR OUTCOMES: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Fabio Salvatore Macaluso; R. Orlando; Walter Fries; M. Scolaro; Antonio Magnano; Dario Pluchino; M. Cappello; Gaetano Cristian Morreale; S. Siringo; A. Privitera; Concetta Ferracane; N. Belluardo; Nadia Alberghina; M. Ventimiglia; G. Rizzuto; Sara Renna; Mario Cottone; Ambrogio Orlando


UEG Week 2017 | 2017

The sicilian network for inflammatory bowel disease (SN-IBD): preliminary data on efficacy of biological therapy.

Ambrogio Orlando; Fabio Salvatore Macaluso; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; R. Di Mitri; N. Belluardo; G. Scarpulla; G. Magrì; A. Trovatello; Antonio Carroccio; S. Genova; C. Bertolami; R. Vassallo; Claudio Romano; Salvatore Pellegrino; M. Citrano; Salvatore Accomando; M. Ventimiglia; Sara Renna; R. Orlando; G. Rizzuto; E. Vinci; Mario Cottone


Journal of Crohns & Colitis | 2017

P412 The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy

Ambrogio Orlando; Fabio Salvatore Macaluso; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; R. Di Mitri; N. Belluardo; G. Scarpulla; G. Magrì; N. Trovatello; Antonio Carroccio; S. Genova; G. Calandruccio; R. Vassallo; Claudio Romano; S. Pellegrino; M. Citrano; Salvatore Accomando; M. Ventimiglia; Sara Renna; R. Orlando; G. Rizzuto; E. Vinci; Mario Cottone


Digestive and Liver Disease | 2017

OC.06.2: The Sicilian Network of Biological Therapy in Inflammatory Bowel Disease: Preliminary Data from a Prospective Study on Efficacy and Safety

Ambrogio Orlando; Walter Fries; A. Privitera; M. Cappello; S. Siringo; Gaetano Inserra; Antonio Magnano; R. Di Mitri; N. Belluardo; G. Scarpulla; G. Magrì; A. Trovatello; Antonio Carroccio; S. Genova; G. Calandruccio; R. Vassallo; Claudio Romano; G. Magazzù; M. Citrano; Salvatore Accomando; M. Ventimiglia; Sara Renna; R. Orlando; G. Rizzuto; E. Vinci; Fabio Salvatore Macaluso; Mario Cottone

Collaboration


Dive into the N. Belluardo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge